Guided Therapeutics (Norcross, GA) is now shipping its single-use disposable Cervical Guide that works with the company's LuViva Advanced Cervical Scan platform, a biophotonic system that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue.
Related: Guided Therapeutics begins FDA premarket approval process for cervical cancer detector
Screening women for cervical cancer offers one of the largest opportunities available in diagnostic medicine, as cervical cancer is linked to human papillomavirus (HPV; a sexually transmitted disease). In the developing world, there are approximately 2 billion women aged 15 and older who are potentially eligible for screening with LuViva. Screening for cervical cancer in the developing world also presents the opportunity to work with governments, who can provide immediate access to large numbers of lives covered under national or regional governmental healthcare programs.
Gene Cartwright, CEO and president of Guided Therapeutics, says that the company will be introducing the new Cervical Guides in the coming months in 2016 in Turkey, Bangladesh, Indonesia, Kenya, and Nigeria, where it is actively working with distributors to implement government-sponsored screening programs. The number of screening candidates in those countries is approximately 246 million and represents three of the 10 most populous countries in the world, he adds.
Internationally, the company has regulatory approval to sell LuViva in Europe, which became effective in January 2014. LuViva has marketing approval from Health Canada, COFEPRIS (Mexico), the Ministry of Health (Kenya), and the Singapore Health Sciences Authority.
For more information, please visit www.guidedinc.com.
